However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months. 
Testosterone esters were synthesized for the first time in 1936, and were found to have greatly improved potency relative to testosterone.  Among the esters synthesized, testosterone propionate was the most potent, and for this reason, was selected for further development, subsequently being marketed.  Testosterone propionate was introduced in 1937 by Schering AG in Germany under the brand name Testoviron.  It was the first ester of testosterone to be introduced,  and was the major form of testosterone used medically before 1960.  In the 1950s, longer-acting testosterone esters like testosterone enanthate and testosterone cypionate were introduced and superseded testosterone propionate.  Although rarely used nowadays due to its short duration,  testosterone propionate remains medically available.